dimecres, 21 de maig del 2014

Medtronic CEO: I'd do Ardian, CoreValve acquisitions all over again




Medtronic CEO Omar Ishrak says he'd acquire Ardian and CoreValve again, despite the high-profile failure of a clinical trial for Ardian's Symplicity renal denervation device and a CoreValve settlement with Edwards Lifesciences that could end up costing more than $1 billion.





Medtronic CEO: I'd do Ardian, CoreValve acquisitions again



read more






from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1i4iYMg

Cap comentari:

Publica un comentari a l'entrada